To hear about similar clinical trials, please enter your email below
Trial Title:
DLCS for Predicting Neoadjuvant Chemotherapy Response
NCT ID:
NCT05617469
Condition:
Gastric Cancer
CT Images
Deep Learning
Neoadjuvant Chemotherapy
Tumor Regression Grade
Conditions: Official terms:
Stomach Neoplasms
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
develop and visualized a radio-clinical signatures from pretreatment oversampled CT images
Description:
develop and visualized a radio-clinical signatures from pretreatment oversampled CT
images to predict the neoadjuvant chemotherapy response and prognosis
Summary:
The early noninvasive screening of patients suitable for neoadjuvant chemotherapy (NCT)
is essential for personalized treatment in locally advanced gastric cancer (LAGC). The
aim of this study was to develop and visualized a radio-clinical biomarker from
pretreatment oversampled CT images to predict the response and prognosis to NCT in LAGC
patients.
Criteria for eligibility:
Study pop:
patients with histologically confirmed GC/esophagogastric junction cancer (EGJC) who
received NCT prior to surgical resection
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1) patients with GC/EGJC confirmed by pathological examination; 2) patients who
underwent D2 lymphadenectomy; 3) patients who received at least two cycles of
preoperative chemotherapy; 4) patients with negative resection margins; and 5)
patients with complete CT image data and clinical data.
Exclusion Criteria:
1) patients unable to undergo D2 radical gastrectomy after neoadjuvant therapy; and 2)
patients with incomplete CT images and clinical data.
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Locations:
Facility:
Name:
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Address:
City:
Hangzhou
Zip:
310022
Country:
China
Status:
Recruiting
Contact:
Last name:
Xiangdong Cheng, MD
Phone:
+0086-0571-88128041
Email:
Chengxd516@126.com
Start date:
July 1, 2022
Completion date:
July 31, 2023
Lead sponsor:
Agency:
Zhejiang Cancer Hospital
Agency class:
Other
Source:
Zhejiang Cancer Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05617469
